Viewpoint: Why NICE is right to promote wider statin use

NICE should be congratulated for its plan to lower the threshold for statin use, but it should be recommending lower doses, writes Berkshire GP Dr George Kassianos.

Dr Kassianos: NICE should recommend lower doses of statins
Dr Kassianos: NICE should recommend lower doses of statins

For the first time, as regards to appropriate lipid management in primary care, I am going to congratulate NICE on both counts: the lowering of the 10-year cardiovascular disease risk [threshold] to 10% from 20%, and the recognition that simvastatin must be left aside in favour of the more effective atorvastatin, which exhibits a much better side-effect profile than simvastatin.

The dose of atorvastatin 20mg is a good choice, but I would be starting with 10mg because 75% of the benefit of any statin is achieved with the lowest licensed dose of a statin. In the case of atorvastatin 10mg, the side effects, such as myalgia, are much rarer and far better tolerated.

The JUPITER study did show that in primary prevention, the cardiovascular benefit of the statin used (rosuvastatin 20mg) was evident above and below 10% 10-year cardiovascular disease risk.

In my view, NICE should indicate ≥10% 10-year cardiovascular disease risk, but also leave it to the discretion of the clinicians to prescribe atorvastatin 10mg for some specific patients with <10% risk.

NICE is now getting on the right track as regards to lipid management. One can ask why did it take NICE so long to see the obvious in lipids, but this debate can be left for another day.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GMC tells BMA to name the doctors responsible for bullying and harassment

GMC tells BMA to name the doctors responsible for bullying and harassment

Senior BMA representatives could face investigation over harassment and bullying...

BMA sexism report backs overhaul to boost representation of women

BMA sexism report backs overhaul to boost representation of women

The BMA should use quotas and minimum thresholds for at least the next decade to...

Key recommendations from the BMA sexism investigation

Key recommendations from the BMA sexism investigation

A damning report into sexism at the BMA, conducted by top barrister Daphne Romney...

Medicines export ban widened as drug shortages continue

Medicines export ban widened as drug shortages continue

The government has added four medicines to the list of products wholesalers are banned...

Damning report on BMA sexism condemns 'failure of leadership'

Damning report on BMA sexism condemns 'failure of leadership'

Whistleblowers have spoken of feeling vindicated after a damning report condemned...

Flawed GP consultation data could distort access targets, BMA warns

Flawed GP consultation data could distort access targets, BMA warns

Flawed data on GP consultations could leave practices facing unfair access targets,...